JP2013177430A5 - - Google Patents

Download PDF

Info

Publication number
JP2013177430A5
JP2013177430A5 JP2013111446A JP2013111446A JP2013177430A5 JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5 JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5
Authority
JP
Japan
Prior art keywords
cells
cancer
killed
dendritic
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013111446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013177430A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013177430A publication Critical patent/JP2013177430A/ja
Publication of JP2013177430A5 publication Critical patent/JP2013177430A5/ja
Pending legal-status Critical Current

Links

JP2013111446A 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 Pending JP2013177430A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518581A Division JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015207617A Division JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Publications (2)

Publication Number Publication Date
JP2013177430A JP2013177430A (ja) 2013-09-09
JP2013177430A5 true JP2013177430A5 (enExample) 2014-06-26

Family

ID=38895372

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2013111446A Pending JP2013177430A (ja) 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Country Status (8)

Country Link
US (1) US20080031900A1 (enExample)
EP (2) EP2037957A4 (enExample)
JP (3) JP2009542714A (enExample)
KR (1) KR20090033375A (enExample)
CN (1) CN101511384A (enExample)
AU (1) AU2007269245B2 (enExample)
CA (1) CA2691346A1 (enExample)
WO (1) WO2008005859A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522835A (ja) * 2008-06-06 2011-08-04 ベイラー リサーチ インスティテュート 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
CA2793458A1 (en) * 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
TW201311895A (zh) * 2011-07-27 2013-03-16 Baylor Res Inst 用於胰臟癌之樹突細胞（ｄｃ）－疫苗療法
WO2013059778A2 (en) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine with gamma interferon
ES2525205T3 (es) 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
KR102367009B1 (ko) 2012-12-28 2022-02-24 암페라 비.브이. 면역원성 용해물의 제조방법, 이로부터 얻어진 면역원성 용해물, 상기 용해물이 로딩된 수지상 세포 및 상기 용해물 또는 상기 수지상 세포를 포함하는 약학 조성물
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
WO2016036319A1 (en) * 2014-09-04 2016-03-10 Agency For Science, Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
US20180066229A1 (en) * 2015-03-17 2018-03-08 Shinshu University Method for preparing dendritic cells via non-adhesive culture using ifn
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
CA3087418A1 (en) * 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
JP2022522802A (ja) * 2019-03-01 2022-04-20 グリットストーン バイオ， インコーポレイテッド Ｔ細胞受容体の選択
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JP2023013211A (ja) * 2021-07-15 2023-01-26 大日本印刷株式会社 細胞医薬品の提供方法、細胞医薬品用ラベルの作成方法、情報処理方法、プログラム、細胞医薬品、細胞医薬品容器および細胞医薬品提供システム
KR20250110348A (ko) 2022-11-23 2025-07-18 제이제이알앤디 엘엘씨 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
WO1999036085A1 (en) * 1998-01-16 1999-07-22 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
JP2007519612A (ja) * 2003-10-15 2007-07-19 イスティチュート スペリオーレ ディ サニータ 結腸直腸癌抗原
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Similar Documents

Publication Publication Date Title
JP2013177430A5 (enExample)
JP2010514455A5 (enExample)
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
Hope et al. Striking a balance—cellular and molecular drivers of memory T cell development and responses to chronic stimulation
JP2014514927A5 (enExample)
JP2015131795A5 (enExample)
Andersen The specific targeting of immune regulation: T-cell responses against Indoleamine 2, 3-dioxygenase
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
MX2013011740A (es) Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
BR112019001656A2 (pt) composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
BR112020015512A2 (pt) método de produção de células exterminadoras naturais e composição para tratamento de câncer
RU2012127685A (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
Liu et al. Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design
JP2018522880A5 (enExample)
JP2014533938A5 (enExample)
Shui et al. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells
Chang et al. Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α
JP2014516538A5 (enExample)
MX2013013243A (es) Medios y metodos para activar la inmunoterapia celular del cancer utilizando celulas cancerosas destruidas mediante presion hidrostatica y celulas dendriticas.
Bagirova et al. Overview of dendritic cell‐based vaccine development for leishmaniasis
JP2012504638A (ja) 能動免疫療法のためのＴｈ１ワクチン接種プライミング
Li et al. Akt promotes irradiation-induced regulatory T-cell survival in hepatocellular carcinoma
AR118282A1 (es) Formulaciones inmunogénicas para el tratamiento del cáncer
AU2018251949A1 (en) Compounds, composition and uses thereof for treating cancer